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Antibiotic-induced modulation of the intestinal microbiota can lead to Clostridioides difficile
infection (CDI), which is associated with considerable morbidity, mortality, and healthcare-
costs globally. Therefore, identification of markers predictive of CDI could substantially
contribute to guiding therapy and decreasing the infection burden. Here, we analyze the
intestinal microbiota of hospitalized patients at increased CDI risk in a prospective, 90-day
cohort-study before and after antibiotic treatment and at diarrhea onset. We show that
patients developing CDI already exhibit significantly lower diversity before antibiotic treat-
ment and a distinct microbiota enriched in Enterococcus and depleted of Ruminococcus, Blautia,
Prevotella and Bifidobacterium compared to non-CDI patients. We find that antibiotic
treatment-induced dysbiosis is class-specific with beta-lactams further increasing enter-
ococcal abundance. Our findings, validated in an independent prospective patient cohort
developing CDI, can be exploited to enrich for high-risk patients in prospective clinical trials,
and to develop predictive microbiota-based diagnostics for management of patients at
risk for CDI.
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C lostridioides difficile is the most common cause of infec-tious antibiotic-associated diarrhea (AAD) and is thepathogen responsible for the largest number of
healthcare-associated infections world-wide1–3. C. difficile infec-
tion (CDI) is characterized by watery stool accompanied by
toxin-mediated inflammation of the bowel where primary risk
factors include hospitalization, age, colonization by toxigenic
C. difficile, and most importantly, antibiotic exposure where use
of fluoroquinolones (FQNs), clindamycin, carbapenems, cepha-
losporins, and penicillins combined with beta-lactamase inhibi-
tors (PBLs) are associated with increased CDI risk4–9. However,
markers predictive of CDI or AAD development are as yet
lacking. Such markers could be utilized to stratify patients into
different risk categories and to enrich patient populations for
clinical trials assessing preventive measures against or ther-
apeutics for CDI.
Patients suffering from CDI, as well as from other forms of
AAD harbor a disrupted intestinal microbiota characterized by
reduced diversity and elevated levels of Enterococcus alongside
reduced levels of members of the Bacteroidetes phylum, the
Lachnospiraceae and Ruminococcaceae families, and Prevotella
spp. during disease manifestation10–20. 16S rRNA gene profiling
provides a useful method for studying changes in microbial
composition. More importantly, it might allow identification of
microbial markers predictive of the risk of CDI development.
Although the microbial composition at CDI onset has been well-
studied, the pre-CDI microbiota remains largely unexplored. To
our knowledge, only one prospective study has investigated
microbial composition as a potential predictor of CDI18,21. This
single-center Canadian study18, part of a larger clinical study
assessing CDI risk factors21, demonstrated that the absence or
reduction in Clostridiales, namely members of Clostridiales
Incertae Sedis XI, in the intestinal microbiota was associated
with an increased risk of CDI18. Collateral damage on the
microbiota induced by antibiotic treatment has been further
shown to result in reduced alpha diversity, as well as an increase
in the presence of antibiotic resistance genes, and long-lasting
effects ranging from weeks to years depending on the
antibiotic22–25. Several small studies in healthy adults have
investigated specific short-term changes induced by antibiotics,
often in combination with multiple compounds25–28. None of
these, however, link antibiotic-induced dysbiosis to development
of CDI.
In this multi-center, observational, prospective study, we
investigated the intestinal microbiota of hospitalized patients aged
50 years and above in 34 hospitals across six European countries
prior to antibiotic therapy with the aim of identifying robust
microbial markers predictive of CDI and AAD development
utilizing 16S rRNA gene profiling combined with a high-
resolution sequence typing approach. Furthermore, longitudinal
perturbations induced by different antibiotic classes were studied
in relation to the CDI-specific and AAD-specific microbiota. Here
we show that patients developing CDI exhibit significantly lower
microbial diversity prior to antibiotic treatment and a distinct
microbiota enriched in Enterococcus and depleted of Rumino-
coccus, Blautia, Prevotella, and Bifidobacterium spp. compared to
non-CDI patients. By validating our findings in an independent
prospective cohort, we show that these microbial markers are
applicable in a geographically diverse patient population. Further,
we show that broad-spectrum antibiotic treatment induces class-
specific dysbiosis with beta-lactam antibiotics particularly
increasing enterococcal abundance. Collectively, our findings can
be exploited to enrich for patients at high risk of CDI develop-
ment in prospective clinical trials and to develop predictive
microbiota-based diagnostics for management of patients at risk
for CDI.
Results
Study population and design. The ANTICIPATE study recruited
1007 patients of which 1002 provided rectal swabs at D1 and 848
at D6 (Fig. 1). Of the 135 patients who developed diarrhea during
a period of 90 days following study inclusion, 15 were diagnosed
with CDI, as described in van Werkhoven et al.29 Stool samples
from 33 of the 135 patients with diarrhea, including 6 patients
diagnosed with CDI, collected at the occurrence of the first
diarrheal episode (S1) were available for analysis (Fig. 1, Table 1).
Following 16S rRNA gene sequencing, 945 and 775 rectal swab
samples collected at D1 and D6, respectively, and S1 samples
from 32 diarrheic patients (including stools from 6 CDI patients)
passed data pre-processing and quality filtering criteria and were
analyzed further. Demographics of the 945 patients included in
this study are detailed in Table 1. In the studied population, 390
patients received antibiotic treatment with drugs belonging to one
of the following classes of broad-spectrum antibiotics: PBLs, other
beta-lactam antibiotics (OBLs), and FQNs (Table 1).
Influence of baseline characteristics—gender, country of origin,
and age by decades—on the fecal microbiome of the 945 patients
was assessed at D1 (Supplementary Table 1). Certain differences
in both alpha and beta diversity were observed in the microbiota,
namely when patients were stratified by countries of origin
(Supplementary Results, Supplementary Table 1, and Supple-
mentary Fig. 1). However, the aim of this study was to identify
biomarkers predictive of CDI that were robust enough to
transcend country, diet, and gender differences in the intestinal
microbiota. Therefore, patients were not stratified by baseline
characteristics.
High-resolution 16S rRNA profiling defines C. difficile pre-
valence. Upon OTU clustering using a 97% cut-off, a single OTU
classified as Clostridium XI was identified in 556 of the 945
(58.8%) patient samples at D1. High-resolution analysis of this
OTU by oligotyping revealed two distinct types of raw reads, one
corresponding to C. difficile and the other to Clostridium bartlettii
(also known as Intestenibacter bartlettii30), a known anaerobic
occupant of the human intestine31 (Supplementary Results).
Oligotyping identified C. difficile in 51 patients (5.40%) at D1
with an average relative abundance of 0.82% (SD= 2.67, Fig. 2a).
Of these, four patients developed CDI within 1–3 days of the
D1 sampling (i.e., study inclusion). Relative abundance of C.
difficile at D1 was slightly higher in the four CDI patients (1.72%,
SD= 2.18) than in the 47 patients who did not develop CDI
within the 90-day study period (0.74%, SD= 2.70). All four CDI
patients underwent treatment with metronidazole and/or vanco-
mycin between the D1 and D6 sampling time-points and in two
patients, C. difficile was not detected at D6.
Of the 945 studied patients, 737 provided both D1 and
D6 samples. C. difficile was detected in 50 patients at D6 (6.78%)
at a 2.5-fold higher average relative abundance (2.02%, SD=
6.14) compared to D1 (Fig. 2b). Only 13 patients carried C.
difficile at both sampling time-points. C. difficile was detected in
all six analyzed stools originating from patients with confirmed
CDI at an average relative abundance of 0.26% (SD= 0.29), and
in two stools from AAD patients that tested negative for CDI with
a relative abundance of 0.01% and 0.02%.
Distinct microbial markers predictive of CDI and AAD
development. Alpha diversity at D1 was lower in patients
developing CDI, compared to those developing AAD or ND
(Fig. 3a, b, p ≤ 0.049). AAD patients also had lower Chao1 indices
compared to ND patients whereas a decreasing trend was
observed in Shannon indices, however, not sufficient to be sig-
nificant (Fig. 3a, b, p= 0.017 and p= 0.087, respectively).
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Furthermore, at D1, the microbiota composition differed
between patients developing CDI and the other two groups
(Fig. 3c, p ≤ 0.025), and between AAD patients and ND patients
(p= 0.002), with the most pronounced differences observed
between CDI and ND patients (p < 0.001).
Microbial composition at D1 was compared between the three
patient groups (CDI, AAD, and ND) for identification of
predictive microbial markers. Patients who developed CDI
harbored elevated levels of the pathobiont Enterococcus (Fig. 3c,
Table 2, and Supplementary Fig. 4). AAD patients harbored
elevated levels of the family Clostridiales Incertae Sedis XI,
Ruminococcus (R. torques, R. faecis, R. lactaris, and Clostridium
glycyrrhizinilyticum), and Blautia spp. (B. wexlerae, B. obeum,
and B. faecis, Supplementary Tables 2–6), whereas ND patients
primarily exhibited a higher abundance of Blautia luti, Prevotella,
uncultured Clostridiales, Porphyromonas (P. bennonis, P. asac-
charolytica, P. uenonis), Campylobacter, and Ezakiella, in addition
to members of the Bifidobacteriales family. When comparing CDI
versus non-CDI (including AAD, ND, and non-CDI tested
diarrheic cases) patients at D1, several OTUs showed lower
abundance among CDI patients, which included six Bifidobacter-
ium spp. and three Blautia spp. B. wexlerae, B. obeum, and B.
faecis (Supplementary Tables 2, 3, and 6).
The OTU with the strongest association at D1 with the
subsequent development of CDI, classified as Enterococcus,
consisted of two types of raw reads distinguished by seven
nucleotides (constituting a 98.4% sequence homology). One was
classified as one or multiple species of the group consisting
of E. hirae, E. villorum, E. ratti, E. faecium, or E. durans (oligotype
1, 63.5% of all OTU reads) and the other as E. faecalis (oligotype
2, 36.5% of all OTU reads) both with 100% sequence identity and
length.
In order to further elucidate the specific species constituting
oligotype 1, we performed shotgun metagenomic sequencing on
D1 samples from patients developing CDI. Oligotype 1 was
primarily constituted by E. faecium and E. villorum correspond-
ing to average relative abundances of 57% and 32%, respectively,
within the oligotype (Supplementary Table 7). Similarly D1 sam-
ples from non-CDI patients underwent shotgun sequencing and
two of the most prevalent OTUs classified as Bifidobacterium spp.
and Blautia spp. were delineated to be Bifidobacterium adoles-
centis, B. catenulatum, B. dentium, and Blautia wexlerae and B.
obeum, respectively (Supplementary Table 7). OTUs classified as
Ruminococcus and Alistipes were also abundant in non-CDI
patients and were further speciated as, R. torques and R. lactaris
as the most prevalent of the oligotypes together with R. bromii,
and A. onderdonkii and A. finegoldia, respectively.
Validation of microbial markers predictive of CDI. To verify
the generalizability and potential of the identified microbiota-based
biomarkers predictive of CDI, we analyzed a previously published
dataset18. This dataset, generated from a Canadian cohort of elderly
patients who developed CDI with matched non-diarrheic patient
Fig. 1 Patient and sample flow in the study. The flow chart provides an overview of participating patients in each processing step, number of samples
collected at each timepoint, and reasons for sample exclusion or non-collection. D1: rectal swab sample collected upon study enrollment. D6: rectal swab
collected ~6 days after initiation and at the end of antibiotic treatment. S1: stool sample collected at the first occurrence of diarrhea (variable time-point).
AAD: patients with non-C. difficile antibiotic-associated diarrhea. CDI: patients with confirmed C. difficile infection. ND: non-diarrheic patients. PBL:
penicillin+ beta-lactamase inhibitor. OBL: other beta-lactamase antibiotics. FQN: fluoroquinolones.
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controls served as an independent validation of the microbial
markers identified in this study to be predictive of CDI. Briefly,
prospective fecal samples had been collected from patients devel-
oping CDI (n= 25) as well as from age-matched and gender-
matched non-diarrheic control patients (n= 25), and resulted in 24
and 25 baseline samples from patients developing CDI and from
non-CDI controls, respectively, after processing. In concordance
with our results, baseline samples from patients who subsequently
developed CDI (median time to development, 5 days) in the vali-
dation dataset also harbored elevated levels of a single enterococcal
OTU (Table 3). Also, in concordance with our data, the OTU
classified as Enterococcus spp. corresponded to two oligotypes, one
classified as E. faecalis (73.81% overall relative abundance) and the
other as E. faecium, E. hirae, E. villorum, E. ratti, or E. durans
(26.19% overall relative abundance, Supplementary Table 7). It was
further noted that 91.7% (n= 22) of the patients who proceeded to
develop CDI within this dataset (n= 24) were colonized by C.
difficile (OTU classified as Clostridium XI) upon study enrollment.
Patients who did not develop CDI in the validation dataset
harbored elevated levels of Ezakiella, Odoribacter, and Rumino-
coccus spp. together with uncultured Clostridiales (Table 3). These
also corresponded to the species identified by oligotyping in our
data (Supplementary Tables 6 and 8).
In addition, several taxa were also unique in the two datasets,
especially those associated with non-CDI patients in our study
were not identified in the validation dataset, and vice versa
(Supplementary Table 9). These differences are likely due to
variable sequencing technologies and depths in either study
(15,000 reads in this study compared to 2000 in the validation
dataset18). Finally, one OTU classified as Finegoldia spp. was
associated with non-CDI patients in the validation dataset
whereas our study revealed it to be linked to patients developing
CDI when compared with non-CDI patients (Table 3). However,
the non-CDI group in our study is constituted by (non-CDI)
AAD as well as ND patients. Further assessment of taxa linked to
CDI and AAD in our study (Supplementary Table 5) revealed
Finegoldia spp. to be primarily associated with patients develop-
ing AAD rather than CDI, thereby correlating with the findings in
the validation dataset.
Antibiotic treatment induces class-specific microbial dysbiosis.
Samples from 390 patients were available for longitudinal analysis
of class-specific antibiotic-induced intestinal dysbiosis. Of these,
194, 133, and 63 patients had received treatment with PBL, OBL,
and FQN, respectively, between the D1 and D6 sampling time-
points (Table 1). Comparison of D1 and D6 samples from the 390
patients showed that treatment with all three antibiotic classes
induced a decrease in alpha diversity together with a shift in beta
diversity of the intestinal microbiota (p < 0.001 for both). Further
investigation into specific changes induced by the individual anti-
biotic classes (PBL, OBL, and FQN) revealed a decrease in both
Shannon (p ≤ 0.007, Fig. 4a) and Chao1 diversity indices (p ≤ 0.011,
Fig. 4b) at D6, together with a change in microbiota composition
(p < 0.001). Comparison of beta diversity distances between D1 and
D6 samples within each antibiotic class showed that patients treated
with OBLs exhibited the largest alterations in microbial composi-
tion compared to those receiving PBLs and FQNs (Fig. 4c). Next,
we compared the microbial compositional differences between the
D1 and D6 samples within each of the three antibiotic classes.
Treatment with all classes resulted in alterations within the four
most dominant phyla of the intestinal microbiota; Firmicutes,
Bacteroidetes, Actinobacteria, and Proteobacteria (Fig. 4d, Supple-
mentary Table 10). The majority of these observed changes affected
members of the Clostridia class. Treatment with beta-lactams (PBL
and OBL) primarily affected members of the Firmicutes phylum
where Clostridiales (primarily Lachnospiraceae members, especially
after OBL treatment), and Lactobacillales were the major affected
orders. FQN treatment resulted in alterations within the same taxa
as beta-lactam treatment, as well as others such as the class Bac-
teroidia, where the Porphyromonadaceae and Prevotellaceae
families were most affected.
Although each antibiotic class resulted in its own unique
dysbiotic microbiota after treatment, some of the observed
changes were also common (Fig. 4d, Supplementary Table 10).
All three classes reduced Streptococcus spp. and increased relative
abundances of Sphingomonas spp. after treatment (Supplemen-
tary Results). Beta-lactam treatment (PBL and OBL) resulted in a
remarkable increase in Enterococcus and Clostridium XIVa spp.
Additionally, PBL and FQN treatment both resulted in reductions
in uncultured Clostridiales, Anaerococcus and Peptoniphilus spp.,
as well as in Porphyromonas and Prevotella spp., both members of
the Bacteroidales order, and in Campylobacter spp. Similarly,
OBL and FQN treatment both resulted in a reduction in
Escherichia/Shigella spp. However, some classes resulted in an
Table 1 Patient demographics of the analyzed study
population.
Total number of patients 945
Age (median [IQR]) 70 [61–79]
Male gender (%) 557 (58.9)
Myocardial infarction (%) 78 (8.25)
Congestive heart failure (%) 134 (14.2)
Peripheral vascular disease (%) 143 (15.1)
Cerebrovascular disease (%) 81 (8.57)
COPD (%) 144 (15.2)
Connective tissue disease (%) 53 (5.61)
Peptic ulcer disease (%) 50 (5.29)
Diabetes mellitus (%) 268 (28.4)
Moderate to severe chronic kidney disease (%) 127 (13.4)
Hemiplegia (%) 16 (1.69)
Leukemia (%) 55 (5.82)
Malignant lymphoma (%) 68 (7.20)
Solid tumor (%) 208 (22.0)
Liver disease (%) 88 (9.31)
AIDS (%) 10 (1.06)
Intestinal obstruction (%) 5 (0.53)
Inflammatory bowel disease (%) 14 (1.48)
Other non-specified comorbidities (%) 538 (56.9)
Has history of CDI (%) 14 (1.48)
Developed CDI within study period (%) 14 (1.48)
Developed AAD within study period (%) 64 (6.77)
Country of origin
France (%) 210 (22.2)
Germany (%) 145 (15.3)
Greece (%) 85 (8.99)
The Netherlands (%) 14 (1.48)
Romania (%) 184 (19.5)
Spain (%) 307 (32.2)
Antibiotic treatment received from D1 to D5
Penicillin+ beta-lactamase inhibitor (PBL, %) 194 (20.5)
Other beta-lactam antibiotics (OBL, %) 133 (14.1)
Fluoroquinolones (FQN, %) 63 (6.67)
Combination therapy and other (%) 347 (36.7)
Patients without a D6 sample (%) 208 (22.0)
IQR interquartile range, COPD chronic obstructive pulmonary disease, AIDS acquired immune
deficiency syndrome, AAD patients with non-C. difficile antibiotic-associated diarrhea, CDI
patients with confirmed C. difficile infection, D1 rectal swab sample collected upon study
enrollment, D6 rectal swab collected ~6 days after initiation and at the end of antibiotic
treatment.
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Fig. 2 C. difficile and C. bartlettii carriage in the analyzed population at D1 and D6. Oligotyping revealed diversity within the OTU classified as Clostridium
XI wherein reads were divided into C. difficile (green) and C. bartlettii (blue). a Rectal swab samples collected at the time of study enrollment (D1), and
~6 days later at the end of treatment (D6) harbored reads classified as both C. difficile and C. bartlettii. Patients that were defined as C. difficile carriers due
to the presence of C. difficile reads after oligotyping showed no clear link to clinical outcome. b Similar carriage rates of the OTU Clostridium XI were
identified in patients both at D1 (5.40%, n= 51) and D6 (6.78%, n= 50) with varying relative abundances of C. difficile and C. bartlettii reads as
demonstrated in the Circos plot. Patients at D6 generally show higher relative abundance of C. difficile than of C. bartlettii compared to D1. D1: rectal swab
sample collected upon study enrollment. D6: rectal swab collected ~6 days after initiation and at the end of antibiotic treatment. AAD: patients with non-C.
difficile antibiotic-associated diarrhea. CDI: patients with confirmed C. difficile infection. ND: non-diarrheic patients. NA: patients without known CDI status
and/or early study termination. OTU: operational taxonomic unit.
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opposing effect of the affected taxa; OBL treatment reduced
Staphylococcus spp., whereas the same taxon was found to
increase after FQN treatment. Similarly, PBL treatment reduced
Dialister spp., whereas FQN treatment resulted in an increase.
Additionally, OBL treatment resulted in a reduction of Blautia
spp. among others.
Comparison of the D6 samples of patients receiving any of the
three antibiotic classes showed dysbiotic profiles that were class-
specific (p < 0.001 overall, and ≤0.006 for the pairwise compar-
isons). Patients treated with OBLs harbored the highest levels of
Enterococcus spp. at D6 together with elevated levels of Prevotella
spp., whereas PBL-treated patients harbored elevated levels of
Fig. 3 Characterization of microbial diversity in baseline (D1) samples. a CDI patients (n= 14, brown) display distinctly lower alpha diversity expressed by
the Shannon index compared to AAD (n= 64, blue, p=0.037) and ND patients (n= 669, green, p=0.005) at D1. AAD patients similarly display lower Shannon
diversity compared to ND patients, however not sufficient to be statistically significant (p=0.087). b Both CDI and AAD patients display lower diversity
expressed by the Chao1 index compared to ND patients (p=0.001 and 0.017, respectively) at D1. Compared to patients who develop AAD, CDI patients display
lower Chao1 indices (p=0.049). c Cladogram generated by LEfSe demonstrating significantly higher abundances of Actinobacteria, Alphaproteobacteria, and
Enterococcus spp. in the gut microbiota of CDI patients at baseline (D1) compared to AAD and ND patients. The cladogram shows distinctly abundant taxa of
interest. For more details, see Supplementary Fig. 4. Alpha diversity indices were compared using the non-parametric two-sided Wilcoxon rank sum test followed
by Bonferroni correction of p-values. Box plots indicate median (middle line), 25th, 75th percentile (box), and 5th and 95th percentile (whiskers) as well as
outliers (gray single dots). AAD: patients with non-C. difficile antibiotic-associated diarrhea. CDI: patients with confirmed C. difficile infection. ND: non-diarrheic
patients. LEfSe: Linear discriminant analysis effect size. LDA: linear discriminant analysis score. *p < 0.05. **p≤0.01. ***p≤0.001.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22302-0
6 NATURE COMMUNICATIONS |         (2021) 12:2241 | https://doi.org/10.1038/s41467-021-22302-0 | www.nature.com/naturecommunications
Escherichia/Shigella compared to patients treated with other
antibiotics (Table 4). Similar to OBL-treated patients, patients
receiving PBLs also harbored increased levels of Prevotella spp. at
D6, but distinct members of this genus compared to those
observed after OBL treatment. FQN treatment resulted in a higher
relative abundance of members of the Lachnospiraceae and
Ruminococcaceae families as well as Blautia spp. (Table 4).
Large alterations in microbial composition in AAD and CDI
patients. To better understand associations between antibiotic-
induced perturbations in the intestinal microbiota and the
occurrence of diarrhea, we determined alterations in alpha and
beta diversity between D1, D6, and at the time of first diarrheal
onset in 32 patients (S1; AAD n= 26, CDI n= 6). The median
time to S1 was 6 days (Interquartile range [IQR]: 3–24) for
patients with AAD. A decreasing trend in overall diversity
described by the Shannon index was observed in patients with
AAD between D1, D6, and S1 samples (Fig. 5a, p ≤ 0.018), indi-
cating that the dysbiosis induced by antibiotic treatment wor-
sened at the onset of diarrhea. Microbial richness described by the
Chao1 index revealed a slight decrease between D1 and D6 as well
as between D1 and S1 (Friedman rank sum: p= 0.054, Fig. 5b).
Additionally, multi-dimensional scaling (MDS) revealed a shift in
microbial composition between different time-points with the
largest differences observed between D1 and S1 (Fig. 5c), pri-
marily due to decreasing abundances of the Proteobacteria phy-
lum, and the Clostridia and Bacteroidia classes. Members of the
Clostridiales Incertae Sedis XI family were significantly reduced,
together with Prevotella, Escherichia/Shigella, and Finegoldia
amongst others (Fig. 5d, Supplementary Fig. 5). Further, a
remarkable shift in members of the Firmicutes phylum was
observed between D1 and S1 samples of AAD patients: from
dominance of Clostridia to an increasing proportion of Bacilli,
wherein Lactobacillales increased in relative abundance together
with Enterococcus, Streptococcus, Lactobacillus, and Akkermansia.
Interestingly, the increase in Enterococcus in the AAD-associated
microbiota (S1 samples) was due to the same OTU that was
identified in this study as a predictive marker of CDI develop-
ment and that also increased after PBL and OBL treatments.
Due to the low number of stool samples obtained from patients
with ongoing CDI, the alterations in microbial composition
observed at the occurrence of CDI (S1) compared to that
observed at baseline (D1) were less well-defined. However, many
similarities were observed between the AAD and CDI microbiota
(Supplementary Fig. 6, Supplementary Results). At the occurrence
of diarrhea, both the CDI and AAD microbiota were vastly
dominated by Firmicutes, whereas the abundance of Bacteroi-
detes and Proteobacteria was reduced. In addition, both the CDI
and AAD microbiota (S1 samples) showed elevated levels of
Enterococcus and a drastic decrease in Prevotella spp.
Discussion
In this prospective study, we performed longitudinal character-
ization of the intestinal microbiota of 945 hospitalized patients
from six European countries included in the ANTICIPATE study
based on known risk factors for development of CDI. Our pri-
mary aim was to identify specific microbial markers or patterns in
the intestinal microbiota predisposing to CDI and AAD that
could be detected in asymptomatic patients at the time of hospital
Table 2 Identification of microbiota-based markers at D1.
Group OTU LDA p-value Genus
AAD Otu9 4.25 0.0423 Finegoldia
Otu30 3.85 0.0280 Blautia
Otu31 3.66 0.0207 Ruminococcus2
Otu106 3.32 0.0131 Uncultured Clostridiales
Otu165 2.66 0.0402 Uncultured Lachnospiraceae
Otu300 2.81 0.0054 Odoribacter
CDI Otu1 4.29 0.0002 Enterococcus
Otu143 3.75 0.0421 Phenylobacterium
Otu163 3.28 0.0455 Dorea
Otu359 2.87 0.0169 Oscillibacter
ND Otu56 3.79 0.0048 Porphyromonas
Otu69 3.59 0.0047 Porphyromonas
Otu648 3.18 0.0035 Blautia
Otu2540 3.37 0.0401 Ruminococcus
Otu127 3.33 0.0001 Oscillibacter
Otu137 3.11 0.0354 Uncultured Lachnospiraceae
Otu1026 2.86 0.0277 Uncultured Lachnospiraceae
Otu974 3.06 0.0003 Roseburia
Otu262 2.58 0.0055 Butyricoccus
Otu294 2.85 0.0309 Uncultured Lachnospiraceae
Otu399 2.94 0.0006 Uncultured
Ruminococcaceae
The microbiota of patients developing CDI (n= 14) and AAD (n= 64), and ND patients (n=
699) was compared to identify predictive biomarkers at D1. Distinctly abundant OTUs
associated with each condition were identified using linear discriminant analysis effect size
(LEfSe, LDA > 2.0). AAD: patients with non-C. difficile antibiotic-associated diarrhea. For more
details, see Fig. 3 and Supplementary Fig. 4. CDI: patients with confirmed C. difficile infection,
ND: non-diarrheic patients, D1: rectal swab sample collected upon study enrollment, LDA: linear
discriminant analysis score, OTU: Operational taxonomic unit.
Table 3 Validation of identified microbiota-based markers predictive of CDI.
OTU OTU classification ANTICIPATE dataset Validation dataset
Patient group Average relative
abundance (%)
LDA p-value Patient group Average relative
abundance (%)
LDA p-value
Otu1 Enterococcus CDI 1.86 4.27 0.0001 CDI 6.40 4.41 0.0037
Otu9* Finegoldia CDI 4.18 4.32 0.0200 Non-CDI 2.76 3.95 0.0009
Otu31 Ruminococcus2 Non-CDI 1.32 3.53 0.0059 Non-CDI 2.04 3.70 0.0302
Otu64 Ezakiella Non-CDI 0.77 3.59 0.0320 Non-CDI 1.17 3.79 0.0190
Otu106 Uncultured
Clostridiales
Non-CDI 0.34 3.18 0.0117 Non-CDI 1.09 4.06 0.0006
Otu300 Odoribacter Non-CDI 0.20 2.79 0.0496 Non-CDI 0.39 3.64 0.0022
Microbiota-based biomarkers identified in the main study were validated by conducting biomarker identification in an independent patient cohort18. Potential biomarkers associated with CDI (n= 24) and
non-CDI (n= 25) patients were identified in the validation cohort. Distinctly abundant OTUs associated with each condition were identified using linear discriminant analysis effect size (LEfSe, LDA >
2.0). OTU9(*) classified as Finegoldia was associated with patients developing CDI (n= 14) when comparing with non-CDI patients (n= 733) in the main study. The non-CDI group in our study is
constituted by (non-CDI) AAD as well as ND patients, and further investigation (Supplementary Tables 3 and 5) revealed this OTU to be strongly associated with patients developing AAD at D1. AAD:
patients with non-C. difficile antibiotic-associated diarrhea, CDI: patients with confirmed C. difficile infection, ND: non-diarrheic patients, Non-CDI: patients with non-C. difficile diarrhea or non-diarrheic
patients, D1: rectal swab sample collected upon study enrollment, LDA: linear discriminant analysis score, OTU: operational taxonomic unit.
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admission. We also characterized the changes associated with
antibiotic treatment potentially impacting the subsequent risk of
CDI and AAD development. This was achieved using 16S rRNA
profiling combined with a high-resolution sequence typing
approach (oligotyping), and when required, further delineation of
species using shotgun metagenomic sequencing.
At the start of antibiotic treatment, intestinal microbial diver-
sity was lowest in patients who subsequently developed CDI
(median time to development: 18 days, range 1–78) and highest
in patients not developing AAD or CDI. In the low-diversity
microbiota of patients subsequently developing CDI, pathobionts
belonging to the Enterococcus genus were present in significantly
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higher abundances compared to AAD or ND patients. Higher
abundance was attributed to a single OTU classified as Enter-
ococcus, and constituted primarily by E. faecium and E. faecalis,
which are also the two most frequently occurring enterococci in
the human intestine32. We further identified the same OTU in
higher abundance in diarrheic stool samples of patients with CDI
(Supplementary Fig. 6, Supplementary Results), as has also been
repeatedly observed in previous studies analyzing stools from
patients with active CDI10,12–17. Baseline samples of CDI patients
also showed remarkably low abundances of Blautia (mainly B.
wexlerae, B. obeum, and B. luti), Ruminococcus (R. torques, R.
lactaris, and R. bromii), Porphyromonas (P. bennonis and P.
uenonis), Bifidobacteria (B. adolescentis, B. catenulatum, and B.
dentium), Odoribacter, and Ezakiella spp. in comparison to non-
CDI patients.
In order to validate our results in independent patient cohorts,
we screened the literature for studies in CDI patients with a
prospective sampling design, and identified one study that had
investigated the microbial composition of the intestinal micro-
biota in patients prior to CDI development18. This dataset, gen-
erated from a Canadian cohort of elderly patients who developed
CDI and from non-diarrheic controls served as an independent
validation to verify the generalizability and predictive potential of
the microbiota-based markers identified here. Reanalysis of this
decade-old Canadian dataset, which was generated using a dif-
ferent sequencing technology than that utilized in this study, also
revealed a low-diversity microbiota with elevated levels of
Enterococcus spp. (mainly E. faecium and E. faecalis) and depleted
of Ruminococcus, Ezakiella, and Odoribacter spp. 5 days prior to
development of CDI in this cohort.
These markers were dichotomized, developed into predictive
OTU ratios or relative abundance thresholds, and after assess-
ment in competing event models, the best predictive ratio was
that of Enterococcus relative to Ruminococcus predictive of a 5-
fold higher risk of CDI in our dataset. The best abundance-based
OTU model utilized relative abundances of Enterococcus relative
to Alistipes and was similarly found to be predictive of a 5-fold
higher CDI risk. Both markers predicted an increased CDI risk in
the Canadian cohort of 4.6 or 6.2 times, respectively, as described
in van Werkhoven et al.29.
Remarkably, treatment with beta-lactams, both PBLs and
OBLs, was also associated with an increased relative abundance of
the enterococcal OTU. Enterococcus spp. are intrinsically resistant
to most cephalosporins and clindamycin, have reduced sensitivity
to staphylococcal-targeting penicillins and carbapenems, and
clinical strains are frequently resistant to FQNs32. Since the 1950s,
ampicillin has been the first choice of treatment of enterococcal
infections33. Yet, since 2000, a specific clade of E. faecium
has become dominant in healthcare settings worldwide and is
characterized by, amongst others, resistance to ampicillin33,34.
Fig. 4 Longitudinal analysis of the impact of antibiotic therapy on the intestinal microbiota. Microbial diversity was compared prior to broad-spectrum
antibiotic treatment at D1 (green) and after treatment at D6 (purple) following treatment with PBLs (n= 194), OBLs (n= 133), and FQNs (n= 63). a A
distinct reduction was observed in Shannon diversity in patients treated with all antibiotic classes (p= 8.98*10−6, p= 2.06*10−5, and p= 0.007,
respectively). b Similarly, distinct reductions in Chao1 diversity was observed following treatment with all antibiotic classes (p= 0.011, p= 0.001, and
p= 9.26 × 10−5, respectively). c Treatment with each antibiotic class resulted in a shift in microbial composition illustrated by the Jaccard distances
between the D1 and D6 samples. d The heatmap illustrates distinctly abundant taxa (LDA > 3.0) identified using LEfSe. For more details, see
Supplementary Table 10. Alpha diversity indices were compared using the paired two-sided non-parametric Wilcoxon signed rank test. Box plots in indicate
median (middle line), 25th, 75th percentile (box), and 5th and 95th percentile (whiskers) as well as outliers (gray single dots). PBL: penicillin+ beta-
lactamase inhibitor. OBL: other beta-lactam antibiotics. FQN: fluoroquinolones. LDA: Linear discriminant analysis score. D1: rectal swab sample collected
upon study enrollment. D6: rectal swab collected ~6 days after initiation and at the end of antibiotic treatment. LEfSe: linear discriminant analysis effect
size. LDA: linear discriminant analysis score. OTU: operational taxonomic unit. *p < 0.05, **p≤ 0.01, ***p≤ 0.001.
Table 4 Characterization of class-specific differences in
microbial composition after broad-spectrum antibiotic
treatment.
Antibiotic class OTU LDA p-value Genus
PBL Otu24 3.97 0.002 Prevotella
Otu2 3.85 0.000 Escherichia/Shigella
Otu1392 3.48 0.004 Clostridium_XlVa
Otu56 3.14 0.019 Porphyromonas
OBL Otu1 4.38 0.000 Enterococcus
Otu21 3.92 0.018 Uncultured
Lachnospiraceae
Otu18 3.83 0.004 Prevotella
Otu48 3.79 0.000 Prevotella
Otu68 3.63 0.045 Alistipes
Otu167 3.51 0.000 Uncultured
Erysipelotrichaceae
FQN Otu30 4.06 0.000 Blautia
Otu43 3.92 0.000 Collinsella
Otu117 3.81 0.000 Roseburia
Otu137 3.78 0.000 Uncultured
Lachnospiraceae
Otu49 3.60 0.012 Uncultured
Ruminococcaceae
Otu3 3.57 0.000 Staphylococcus
Otu75 3.55 0.020 Anaerococcus
Otu163 3.52 0.000 Dorea
Otu527 3.47 0.000 Coprococcus
Otu1026 3.45 0.000 Uncultured
Lachnospiraceae
Otu22 3.38 0.000 Lactobacillus
Otu1086 3.29 0.020 Uncultured
Ruminococcaceae
Otu97 3.26 0.000 Anaerostipes
Otu2858 3.25 0.000 Uncultured
Lachnospiraceae
Otu165 3.12 0.000 Uncultured
Lachnospiraceae
Otu262 3.10 0.000 Butyricicoccus
Otu399 3.10 0.046 Uncultured
Ruminococcaceae
Otu315 3.07 0.000 Uncultured
Lachnospiraceae
Otu3495 3.05 0.001 Fusicatenibacter
Otu252 3.03 0.011 Uncultured
Ruminococcaceae
The microbiota of patients treated with PBLs (n= 194), OBLs (n= 133), and FQNs (n= 63) was
compared at D6 to identify the class-specific impact of broad-spectrum antibiotic treatment.
Distinctly abundant OTUs associated with each timepoint were identified using linear
discriminant analysis effect size (LEfSe, LDA > 3.0). D6: rectal swab collected ~6 days after
initiation and at the end of antibiotic treatment. PBL: penicillin+ beta-lactamase inhibitor. OBL:
other beta-lactamase antibiotics. FQN: fluoroquinolones. LDA: linear discriminant analysis score.
OTU: operational taxonomic unit.
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Further, emergence of vancomycin resistance in this genus,
especially in the E. faecium species, has rendered it the ultimate
hospital-adapted organism34. Prior studies have shown that
vancomycin-resistant enterococci (VRE) colonization of the
intestinal microbiota may protect against acquisition of common
enteric pathogens such as E. coli and GI viruses, and predispose to
increased C. difficile infections35,36. Therefore, it is possible that
the increased colonization with VREs as a result of beta-lactam
therapy heightens the risk of CDI development.
A comparison of baseline (D1) samples from patients devel-
oping CDI and AAD showed lowest diversity in patients devel-
oping CDI followed by those developing AAD, compared to ND
patients as well as the presence of distinctive microbial markers
with Enterococcus spp. and Clostridiales Incertae Sedis XI,
respectively, as being the most characteristic. In contrast, stool
samples from patients with active CDI and AAD exhibited many
similarities, including depletion of Blautia spp. and Prevotella
spp., and an increased enterococcal abundance as also observed
by previous studies10,12,14,15,19. These data indicate a convergent
evolution towards a diarrheic, dysbiotic microbiota and also
suggest that C. difficile might not be the driver underlying the
changes observed in the microbiota, but rather opportunistically
invades an antibiotic-induced low-diversity microbiota abundant
in Enterococcus spp. The latter hypothesis is supported by the lack
of C. difficile carriage in D1 (10/14) and D6 (12/14) samples of
patients later developing CDI in this study. Although the pre-
valence of C. difficile carriage was similar after antibiotic treat-
ment (D6), relative abundances of the organism were distinctly
higher compared to those at D1. Expectedly, C. difficile pre-
valence identified by 16S rRNA-based techniques in the present
study was higher than that of toxigenic C. difficile, identified by
Xpert®C. difficile/Epi panel (Cepheid, CA, USA) in the same set of
patients29, as the former do not discriminate between toxigenic
and non-toxigenicC. difficile. Of note, the majority of patients
Fig. 5 Longitudinal analysis of microbial diversity and dysbiosis in patients developing AAD. Microbial diversity and composition in patients developing
AAD in the study population (n= 26) was assessed at D1 (green), D6 (blue), S1(purple). a Gradual decrease in Shannon diversity was observed between
all timepoints (from D1 to D6: p= 0.018, from D1 to S1: p= 2.74*10−5, from D6 to S1: p= 0.007). b Similar trends are observed for the Chao1 index
(Friedman rank sum: p= 0.054). c Multi-dimensional scaling (MDS) shows distinct clusters for samples collected at each timepoint. d Comparison of the
microbiota composition at D1 and S1 conducted using LEfSe (LDA > 2.0) shows large changes in the Firmicutes and Proteobacteria phyla for AAD patients.
Proteobacteria are significantly reduced at the occurrence of AAD, and a shift is observed from the Clostridia to Bacilli class at the instance of diarrhea. The
cladogram shows distinct taxa of interest. For more details, see Supplementary Fig. 5. Alpha diversity indices were compared using the paired two-sided
non-parametric Wilcoxon signed rank test followed by Bonferroni correction of p-values. Box plots indicate median (middle line), 25th, 75th percentile
(box), and 5th and 95th percentile (whiskers) as well as outliers (gray single dots). AAD: patients with non-C. difficile antibiotic-associated diarrhea. D1:
rectal swab sample collected upon study enrollment. D6: rectal swab collected ~6 days after initiation and at the end of antibiotic treatment. S1: stool
sample collected at the first occurrence of diarrhea (variable time-point). LEfSe: linear discriminant analysis effect size. LDA: Linear discriminant analysis
score. *p < 0.05, **p≤ 0.01, ***p≤ 0.001.
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harboring C. difficile at D6 were distinct from C. difficile-positive
patients at D1, indicating potential nosocomial acquisition of the
organism upon or during antibiotic treatment.
In addition to an overall decrease in alpha diversity after treat-
ment with PBLs, OBLs, and FQNs, we identified distinct changes in
microbiota profiles at D6 linked to each of the three antibiotic
classes. Notwithstanding the enterococcal bloom following beta-
lactam therapy, PBL treatment further led to a reduction in Clos-
tridiales Incertae Sedis XI members. The Clostridiales Incertae Sedis
XI bacterial family has been previously associated with decreased
CDI risk, as a decrease in relative abundance prior to onset of CDI
has been reported18. Here we show that this decrease, resulting from
PBL treatment, was observed in the D6 samples of patients who
eventually developed CDI, AAD, or did not develop diarrhea. OBL
treatment led to large reductions in members of the Lachnospiraceae
family comprising producers of butyrate, a short-chain fatty acid
associated with intestinal health37, suggesting that a reduction might
render patients more susceptible to CDI. Both beta-lactam and FQN
treatment led to a decrease in specific Prevotella spp. that showed
higher abundance in the baseline ND microbiota and were
remarked to be depleted at the time of occurrence of AAD. Col-
lectively, all investigated antibiotic classes significantly altered taxa
with documented links to the development or occurrence of CDI
and AAD further underscoring their role as high-risk antibiotics.
One of the main challenges faced by microbiota studies is the
variability between patients in the study population as no two
patients have the exact same baseline microbiota profile. This makes
evaluation of specific changes difficult and highlights the need for
longitudinal sampling, which is one of the strengths of our study.
The low CDI incidence in hospitalized patients was considered
when designing this study by limiting recruitment to patients
exposed to known risk-factors for CDI, such as broad-spectrum
antibiotic treatment. Despite such efforts, the observed CDI inci-
dence was lower than anticipated, and constitutes a limitation of
this study. Nonetheless, as shown by the independent validation
study performed on patient samples collected a decade prior and
from a different continent, we successfully identified robust
microbial markers predictive of the development of CDI that pre-
vail over confounders commonly limiting the wider applicability of
microbiota-based markers. Future applications include enrichment
of high-risk patients in prospective clinical trials, development of
predictive, microbiota-based diagnostics to tailor antibiotic therapy
or stool biobanking from high-risk patients prior to antibiotic
therapy, exemplifying a precision medicine approach.
Methods
Study design. Samples used in this study were collected in ANTICIPATE (Clin-
icalTrials.gov NCT02896244), a multi-center prospective observational study con-
ducted at 34 European hospitals in Germany, Greece, France, Romania, Spain, and
the Netherlands. Ethical approval was obtained at each participating site in
accordance with local regulations (Supplementary Information) and written
informed consent was obtained from all participants prior to any study-related
procedures. Inclusion criteria, overall patient characteristics, diagnostic algorithms,
etc., are described in detail in van Werkhoven et al.29. Briefly, 1007 hospitalized
patients aged 50 years or above, receiving one or several antibiotics of either
penicillins with a beta-lactamase inhibitor, 3rd or 4th generation cephalosporins,
clindamycin, carbapenems, or FQNs were enrolled between September 2016 and
October 2017 (Fig. 1). Three rectal swabs per patient were collected: two were
collected at study enrollment prior to or within the first 6 h after the start of
antibiotic treatment (D1) where one was used for detection of toxigenic C. difficile
carriage using the Xpert®C. difficile/Epi panel (Cepheid, CA, USA) as described in
van Werkhoven et al.29; the third after 6 days ± 24 h after the start of antibiotic
treatment (D6), or at hospital discharge.
In this study, the second sample collected at D1 paired with the sample collected
at D6 were utilized for fecal microbiota analysis as described below. In case of
diarrhea, defined as loose stool scoring 5–7 on the Bristol Stool chart38 with ≥3
discharges within 24 h, a stool sample was collected for CDI testing during each
episode during the course of the entire 90-day study period. CDI diagnosis was
performed as described by the ESCMID guidelines39. AAD was defined as non-C.
difficile diarrhea confirmed by a negative diagnosis.
Population and sample characteristics. Baseline characteristics were evaluated by
comparing samples grouped by age in decades, country of origin, gender, reason
for hospitalization, hospitalization ward, and comorbidities to study the impact on
the intestinal microbiota. To identify potential biomarkers of CDI and AAD
development, samples collected at D1 were divided into three groups based on
patient outcome; samples originating from patients who developed CDI (n= 14),
confirmed non-C. difficile AAD (n= 64), and non-diarrheic patients (n= 669)
who completed the 90-day study period, referred to as CDI, AAD, and ND
patients, respectively. Patients prematurely lost to follow-up due to withdrawal of
consent (n= 81) or death (n= 77), and patients with diarrheal episodes that did
not undergo CDI testing (n= 40) were excluded for this analysis. Studies related to
the specific effect of different antibiotics on the microbiota were conducted on
samples from patients who provided both a D1 and a D6 sample (n= 737). These
were divided into groups according to received antibiotics classified according to
the 2019 ATC index (WHO Collaborating Centre for Drug Statistics Methodology,
https://www.whocc.no/) based on their mode of action and chemistry. All anti-
biotics received between study enrollment (D1) and up to one day prior to col-
lection of the second rectal swab at D6 were considered for classification. Patients
who received antibiotics belonging to only one class, irrespective of number of
treatments, number of different antibiotics received within the same class, or
duration, were considered for analysis whereas patients receiving combination
treatment or treatment with antibiotics belonging to more than one class were
excluded. The three studied antibiotic classes were PBLs (namely penicillins with
extended spectrum); OBLs (namely cephalosporins and carbapenems); and FQNs.
In cases where stool samples were sequenced, temporal analysis of patients who
developed CDI and AAD was conducted at D1, D6, and the onset of the first
diarrheal episode (S1).
Sample collection and DNA isolation. Rectal swab samples were collected by
inserting swabs (FecalSwab Regular Flocked Collection Kit, Copan Diagnostics Inc.,
Murrieta, USA) 2 cm into the rectum in a rotating manner and stored at –80 °C
within 4 h of collection. In case of diarrhea, a stool sample was collected for CDI
testing during each episode by patients and transported under refrigerated con-
ditions to the local hospital lab and subsequently stored at –80 °C. Total metage-
nomic DNA was extracted from thawed fecal samples using the FastDNA SPIN Kit
(MP Biomedicals, Santa Ana, USA) according to the manufacturer’s instructions.
Each DNA extraction batch was processed with a blank swab as a negative control.
DNA quantity was assessed by using the Qubit ds DNA HS Assay Kit with a Qubit
3.0 Fluorometer (ThermoFisher Scientific, Waltham, USA). In case of insufficient
DNA concentration for library preparation, samples were concentrated using a
Savant DNA120 SpeedVac (Thermo Scientific, Waltham, USA) and dissolved in
30 μl double-distilled water.
16S rRNA gene sequencing. 16S rRNA gene libraries were prepared using the
Nextera XT kit (Supplementary Methods, Supplementary Table 11) and sequenced
using 2 × 250 or 2 × 300 paired-end sequencing as described by the manufacturer
(Illumina Inc., San Diego, USA). The average number of raw reads in the
sequenced samples was 80,145 (range 1–1,343,956) with a sequencing error rate of
0.01% (Supplementary Fig. 8). In case of failed sequencing due to low sample
concentration, negative PCRs, low number of reads (<20,000 raw or <15,000
processed reads, Supplementary Fig. 8), or poor read quality (Phred score < 25,
Supplementary Fig. 9), sequencing was repeated. DNA from four pure C. difficile
isolates, mock communities consisting of pooled 16S rRNA gene sequences of 20
bacterial strains (HM-783D, https://www.beiresources.org/), and extracted DNA
from previously sequenced samples were included as positive sequencing controls,
together with negative PCR and DNA extraction controls to ensure sequencing
reproducibility (Supplementary Figs. 11–13).
16S rRNA gene profiling
Pre-processing, quality filtering, and classification. Data pre-processing was per-
formed using the OCToPUS v1.0 pipeline40, which starts by de-noising each of the
forward and reverse raw reads separately using the implemented k-mer frequency
in SPAdes v3.5.041. Contigs were created by heuristically merging de-noised
paired-end reads in mothur v.1.39.142,43. Contigs with base ambiguities, repre-
senting Phred scores below 25 or unresolved mismatches between forward and
reverse reads, were discarded, whereas the remaining contigs were aligned to the
SILVA database v.11944. Contigs aligning outside the V3–V4 region were discarded
together with contigs containing more than eight homopolymers, and with
unexpected length. Denoising of the trimmed sequence alignment was conducted
with the Illumina Paired-End Denoiser (IPED) algorithm v1.045 followed by de
novo chimera removal with CATCh v1.046. OTU clustering was performed with
UPARSE (USEARCH v8.1.186 implementation) at a 97% identity level47, followed
by taxonomic classification against the Ribosomal Database Project (RDP) dataset
v. 16 using the default cutoff of 80%48.
Primary data analysis. Further stratification of OTU membership was conducted
for OTUs of interest, such as the OTU classified as Clostridium XI, which contains
C. difficile, using oligotyping v2.249. Oligotyping can distinguish down to single-
nucleotide differences in ribosomal 16S rRNA sequences between species while
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disregarding sequencing errors. Identified oligotypes were classified with NCBI
Nucleotide BLAST using default settings and the Ribosomal 16S rRNA database as
reference. Only hits with an identity >97% were considered. Rarefaction curves
were calculated in mothur, and a sequencing depth of 15,000 reads was chosen as a
tradeoff between coverage and number of discarded samples and was applied to all
samples before further analysis (Supplementary Fig. 9). C. difficile carriage was
determined in all sequenced samples by oligotyping. Alpha diversity indices
Shannon and Chao1 were calculated in mothur together with beta diversity
described by the Jaccard index chosen specifically for its enhanced sensitivity to
rare OTUs compared to other weighted indices.
Statistical analysis and visualization. Statistical comparison of the alpha diversity was
conducted using two-sided non-parametric Kruskal–Wallis or Wilcoxon signed-rank
tests for non-paired comparisons, and paired Friedman rank sum or Mann–Whitney
tests as indicated. In case of multiple-comparison testing, such as when comparing
microbial diversity at several timepoints collected from the same patient or when
comparing diversity between antibiotic groups at D6, Bonferroni correction of p-
values was performed. Analysis of molecular variance (AMOVA), an ANOVA-like
statistical method developed for metagenomic datasets, was used to compare beta
diversity between samples. Further analysis and visualization was performed using the
ggplot2 v3.3.2 and Rhea v.1.6 packages in RStudio v. 3.5.050,51. Microbial biomarker
prediction and identification of significant OTUs (p < 0.05) using Linear Discriminant
Analysis Effect Size (LEfSe) v1.0.0 with an LDA score > 2.0 was performed in
mothur52. For longitudinal analysis of microbial changes as a result of antibiotic
treatment, an LDA score of >3.0 was used to identify the most relevant changes.
p-values < 0.05 were considered significant for all analyses. Only OTUs with an
average relative abundance >0.1% were reported for the LEfSe analyses. The rela-
tionship between C. difficile carrier at D1 and D6 were visualized using Circos53.
Microbiota-based biomarker validation. To assess robustness of the identified
microbiota-based biomarkers in this study, biomarker detection was performed in
an independent validation dataset18. These data (n= 50) were collected from
hospitalized patients aged ≥18 years in 2005–2006 in Canada and contains pro-
spectively collected fecal samples obtained within the first 7 days of hospital
admission. Patients who developed CDI (n= 25) within the 60-day follow-up
period were matched with control patients (n= 25) based on age, gender, and
hospitalization date. Library preparation and sequencing of the V3–V5 regions of
the rRNA gene in this study was conducted using 454 Pyrosequencing.
Raw sequencing data were processed similarly to MiSeq data generated in this
study. First the reads with base ambiguities or homopolymers more than eight
bases were discarded, then aligned to the V3–V4 region of the SILVA database
v.11944, discarding reads failing to fulfill the expected length. Denoising and
chimera removal was performed using mothur and CATCh46, respectively. Lastly,
reads were clustered to the same set of OTUs (excluding rare OTUs with
abundance < 0.1%) with UPARSE at a 97% identity level47, followed by taxonomic
classification against the RDP dataset v. 16. One sample containing only 32
processed reads was removed due to low coverage prior to further analysis. To
identify microbiota-based markers associated with CDI, microbial composition of
samples collected from ND and CDI patients were compared using LEfSe (p < 0.05,
LDA > 2.0). Identified OTUs were further oligotyped as previously described.
Shotgun metagenomic and sequencing. Available DNA quantity of D1 samples
originating from patients who developed CDI in this study (n= 14) was assessed,
and where sufficient amounts remained (n= 9), shotgun metagenomic DNA
libraries were prepared using the Nextera XT kit followed by 2 × 150 bp paired-end
sequencing with a NovaSeq instrument (Illumina Inc., San Diego, USA) with at
least 1,000,000 raw reads per sample according to the manufacturer’s instructions.
Analysis of shotgun metagenomic data. Raw read quality was assessed using
FastQC v0.11.9 (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/), fol-
lowed by adapter trimming using Trim Galore v0.6.4 (https://github.com/
FelixKrueger/TrimGalore). Differentially abundant OTUs defined by LEfSe when
comparing patients who developed CDI follow-up with all others, and their
respective oligotypes classified using NCBI blast against the 16S database, were
used as a basis for taxonomical assignment of shotgun metagenomic reads. A
manually curated Kraken2 database was constructed using representative genomes
obtained from NCBI containing only those species listed in Supplementary Table 6
(Supplementary Table 12). Subsequent taxonomic assignment of trimmed reads
was performed using Kraken 254 v2.0.9 with a confidence score of 1 using the
manually curated database as reference.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Data supporting the findings of this study are available within the paper and its
Supplementary Information file. 16S rRNA and shotgun metagenomic sequence data
generated and analyzed in this study have been deposited in the NCBI Sequence Read
Archive with the accession code PRJNA685914. Human reads were identified and
removed prior to shotgun metagenomics data upload. All other data generated in this
study are available from the corresponding author upon reasonable requests. Raw data
from Vincent et al.18 utilized as a validation cohort in this study was kindly provided by
Prof. Amee Manges (University of British Columbia, Vancouver, Canada). The following
public databases were utilized for analysis in this manuscript: SILVA v.119 (https://
mothur.org/wiki/silva_reference_files/), Ribosomal Database Project (RDP, https://
mothur.org/wiki/rdp_reference_files/) v.16. Source data are provided with this paper.
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